United Therapeutics Corporation - Common Stock (NQ:UTHR)

458.96 -5.97 (-1.28%)

Streaming Delayed Price Updated: 9:37 AM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

3 Market-Beating Stocks to Target This Week

January 15, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the...

Via StockStory

Topics Credit Cards Supply Chain

Investment Advisor Doubles Down on Insurance Stock, According to Recent SEC Filing ↗

January 15, 2026

This specialty insurer delivers tailored property and casualty coverage for commercial and individual clients across diverse sectors.

Via The Motley Fool

Topics Bonds Regulatory Compliance

Nepsis Bets on CAVA's Future Growth Plan With $2.9 Million Purchase ↗

January 15, 2026

This fast-casual chain pairs Mediterranean dining with grocery retail, leveraging a vertically integrated, multi-channel strategy.

Via The Motley Fool

Topics Regulatory Compliance

2 Cash-Heavy Stocks to Target This Week and 1 We Question

January 11, 2026

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From United Therapeutics Corporation

Via Business Wire

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

December 21, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.

Via StockStory

Topics Artificial Intelligence

Why a $27 Million Buy Signals New Confidence in Weatherford Stock ↗

December 09, 2025

One global services provider just landed a long list of new contracts — and a major fund has quietly built a sizable stake.

Via The Motley Fool

Topics Regulatory Compliance

Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy? ↗

December 09, 2025

One major fund is betting that Signet’s margin rebound is just getting started.

Via The Motley Fool

Topics Regulatory Compliance

Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock ↗

December 09, 2025

One value-focused hedge fund just doubled down on one of North America’s biggest coal exporters — here’s what that could mean for the stock’s next chapter.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake? ↗

December 09, 2025

Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake?

Via The Motley Fool

Topics Regulatory Compliance

United Therapeutics Corp (NASDAQ:UTHR): A Value Investing Case Study ↗

December 05, 2025

United Therapeutics (UTHR) presents a compelling value investment case with strong profitability, a debt-free balance sheet, and a valuation discounted relative to its biotech sector peers.

Via Chartmill

United Therapeutics Corp (NASDAQ:UTHR): A Caviar Cruise Quality Investment ↗

November 26, 2025

United Therapeutics (UTHR) excels as a Caviar Cruise quality stock with strong growth, high profitability, a debt-free balance sheet, and exceptional returns on capital.

Via Chartmill

2 Mooning Stocks on Our Buy List and 1 That Underwhelm

November 21, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today ↗

November 19, 2025

Via Benzinga

United Therapeutics Corp (NASDAQ:UTHR) Presents a Compelling Value Investment Case ↗

November 12, 2025

United Therapeutics (UTHR) offers strong value with a low P/E ratio, zero debt, and high profitability. This biotech stock presents a compelling opportunity for value investors.

Via Chartmill

3 Reasons Investors Love United Therapeutics (UTHR)

November 09, 2025

United Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 44.4%, reaching $448.91 per share. This performance may have investors wondering how to...

Via StockStory

Is United Therapeutics Corp Gaining or Losing Market Support? ↗

November 07, 2025

Via Benzinga

P/E Ratio Insights for United Therapeutics ↗

November 07, 2025

Via Benzinga

My Top Vanguard Index ETF Pick for 2026 ↗

November 06, 2025

This ETF has underperformed the S&P 500 lately, but I think that will change.

Via The Motley Fool

Topics ETFs Economy Stocks

The 5 Most Interesting Analyst Questions From United Therapeutics’s Q3 Earnings Call

November 05, 2025

United Therapeutics delivered a quarter that was well received by the market despite missing revenue expectations, as operational progress and clinical milestones took center stage. Management credited...

Via StockStory

Topics Earnings Intellectual Property

If You Invested $100 In United Therapeutics Stock 5 Years Ago, You Would Have This Much Today ↗

November 04, 2025

Via Benzinga

United Therapeutics Corporation to Present at Upcoming Investor Conferences

November 04, 2025

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

November 03, 2025

From United Therapeutics Corporation

Via Business Wire

2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid

November 02, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

United Therapeutics Corp (NASDAQ:UTHR) Offers Affordable Growth with Strong Profitability ↗

October 31, 2025

United Therapeutics offers strong growth, high profitability, and a robust balance sheet, yet trades at a significant discount to the biotech industry. A top pick for affordable growth.

Via Chartmill

United Therapeutics (UTHR) Earnings Transcript ↗

October 30, 2025

United Therapeutics (UTHR) Earnings Transcript

Via The Motley Fool

Topics Earnings Intellectual Property

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook

October 30, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 6.8% year on year to $799.5 million. Its GAAP profit of $7.16 per...

Via StockStory

Why Is United Therapeutics (UTHR) Stock Soaring Today

October 29, 2025

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 11.7% in the afternoon session after the company reported record third-quarter financial results and announced positive outcomes...

Via StockStory

S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? ↗

October 29, 2025

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100...

Via Benzinga

Topics Economy Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.